Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine
Related Experiment Video
Updated: Jun 22, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Toshiki Mizuno1, Masaki Kondo, Noriko Ishigami
1Department of Molecular Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan. mizuno@koto.kpu-m.ac.jp
Abstract:
A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Hepatic Encephalopathy
Dementia l: Introduction
Cerebral Edema ll: Pathophysiology
Cerebral Edema l: Introduction
